Downloads: 28

Files in This Item:
File Description SizeFormat 
s41598-020-78334-x.pdf911.89 kBAdobe PDFView/Open
Title: Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
Authors: Morita-Fujita, Mari
Arai, Yasuyuki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-9662-5093 (unconfirmed)
Yoshioka, Satoshi
Ishikawa, Takayuki
Kanda, Junya  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-6704-3633 (unconfirmed)
Kondo, Tadakazu
Akasaka, Takashi
Ueda, Yasunori
Imada, Kazunori
Moriguchi, Toshinori
Yago, Kazuhiro
Kitano, Toshiyuki
Yonezawa, Akihito
Nohgawa, Masaharu
Takaori-Kondo, Akifumi
Kyoto Stem Cell Transplantation Group (KSCTG)
Author's alias: 新井, 康之
吉岡, 聡
石川, 隆之
諫田, 淳也
近藤, 忠一
赤坂, 尚司
上田, 恭典
今田, 和典
森口, 寿徳
野吾, 和宏
北野, 俊行
米澤, 昭仁
直川, 匡晴
髙折, 晃史
Keywords: Epidemiology
Outcomes research
Issue Date: 8-Dec-2020
Publisher: Springer Nature
Journal title: Scientific Reports
Volume: 10
Thesis number: 21418
Abstract: Since the introduction of leukemia-type induction therapies for T-cell lymphoblastic lymphoma (T-LBL), improvements in the long-term outcomes of T-LBL have been reported. However, indications for and the appropriate timing of hematopoietic stem cell transplantation (HSCT) have not yet been established. Therefore, we performed a multicenter retrospective cohort study of patients with T-LBL treated using leukemia-type initial therapies to compare the outcomes after HSCT at different disease stages. We enrolled 21 patients with T-LBL from a total of 11 centers, and all patients received hyper-CVAD as a leukemia-type initial regimen. HSCT was performed during the CR1/PR1 (standard disease) stage in 11 patients, while it was completed at a later or non-remission (advanced disease) stage in 10 patients. Following HSCT, the overall survival rate was significantly greater in standard disease than in advanced-disease patients (79.5% vs. 30.0% at 5 years; hazard ratio (HR) 5.97; p = 0.03), with trend to the lower incidence of relapse in the former group (27.3% vs. 60.0% at 5 years; HR 2.29; p = 0.19). A prognostic difference was not detected between cases treated with allogeneic and autologous HSCTs. Our study suggests that frontline HSCT may be a feasible treatment option for T-LBL, even in the era of leukemia-type initial therapy.
Rights: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
URI: http://hdl.handle.net/2433/261674
DOI(Published Version): 10.1038/s41598-020-78334-x
PubMed ID: 33293600
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.